After to a split advisory committee vote last month on Chiron Corp.'s Pulminiq, the FDA issued an approvable letter but asked for another study to confirm efficacy of the lung transplant drug. (BioWorld Today)
In late December 2003, when Pfizer Inc. agreed to buy out Esperion Therapeutics Inc. for $1.3 billion - $35 per share, which amounted to a 54 percent premium to the average closing price during the previous 20 days - the pharmaceutical giant paid big for an opportunity that seemed even bigger.
RSS